Line 131: |
Line 131: |
| |Less common but more aggressive in children | | |Less common but more aggressive in children |
| |PMID:25965575; PMCID:3991130; PMID:20425037; PMID:25957288; PMID:25965575; PMID:22516549 | | |PMID:25965575; PMCID:3991130; PMID:20425037; PMID:25957288; PMID:25965575; PMID:22516549 |
| + | |- |
| + | | |
| + | |Ependymoma, RELA fusion-positive, WHO grade II or III |
| + | |'''Gain:''' 1q<br> |
| + | '''Aneuploidy:''' multiple chromosomes lost and gained<br> |
| + | '''Chromothripsis:''' chromosome 11 (70% of supratentorial tumors) |
| + | |'''Fusion:''' c11orf95-RELA (supratentorial tumors)<br> |
| + | '''Loss:''' CDKN2A/B (may help distinguish from other supratentorial ependymomas) |
| + | |Unfavorable prognosis; occur in infants or children |
| + | |PMID:25965575; PMID:24553141; PMID:28371821 |
| + | |- |
| + | | |
| + | |Anaplastic ependymoma (no WHO grade assigned) |
| + | |Epigenetic studies suggest range of abnormalities: balanced or unbalanced genomes |
| + | |'''Mutation:''' NF2 (including germline) in spinal tumors<br> |
| + | '''Fusion:''' RELA fusions, YAP1 fusions can correspond to anaplastic histology |
| + | |Mostly intracranial tumors, rarely in spinal cord; YAP1 fusion tumors can occur in infants |
| + | |PMID: 25965575 |
| + | |- |
| + | |'''EMBRYONAL TUMORS''' |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |WHO CNS Tumors (2016) |
| + | |- |
| + | |Medulloblastoma |
| + | |WNT-activated |
| + | |'''Loss:''' monosomy 6/6q- as sole finding in 85% |
| + | |'''Mutation:''' CTNNB1, DDX3X, TP53, SMARCA4, KMT2D, APC (germline mutations in Turcot syndrome) |
| + | |Common in children > 3 years of age; typically show classic histology, rarely metastasize; overall favorable prognosis |
| + | |PMID:22832581, PMID:24493713; PMID:22134537 PMID:24894640; PMID:16258095; PMID:22832581 PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768 PMID:20940197; PMID:23175120 |
| + | |- |
| + | | |
| + | |SHH-activated |
| + | |'''Gain:''' 3q<br> |
| + | '''Loss:''' 9q, 10q, 17p<br> |
| + | '''Ploidy changes:''' Tetraploidy associated with chromothripsis and TP53 mutations<br> |
| + | '''Chromothripsis:''' associated with TP53 mutation |
| + | |'''Mutation:'''<br> |
| + | '''TP53 wild-type tumors:''' PTCH1 (germline mutations in Gorlin syndrome), SMO, SUFU (can be germline), TERT promoter<br> |
| + | '''TP53-mutant tumors:''' can be germline<br> |
| + | '''Loss:''' PTCH1, PTEN<br> |
| + | '''Amplification:''' GLI2 (TP53-mutant tumors), IGF1R, PPM1D, MYCN (TP53-mutant tumors), YAP1, MIR17/92, MDM4 |
| + | |Common in infants, rare in children, most common type of medulloblastoma in adults; Desmoplastic (or nodular) histology common; TP53 wild-type usually correlate with extensive nodularity or desmoplastic histology; TP53-mutant tumors correlate with metastatic disease |
| + | |PMID:24651015; PMID:21681522; PMID:22832581 PMID:24493713; PMID:24077351; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457 PMID:25043047; PMID:22820256; PMID:26976201 PMID:20823417; PMID:22265402; PMCID:3889646 PMID:16567768; PMID:20940197; PMID:23175120 |
| |- | | |- |
| | | | | |
| | | | | |